Lercanidipino Tevagen

Lercanidipine, the active ingredient in Lercanidipino Tevagen, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension by relaxing vascular smooth muscle and lowering peripheral resistance. GNH USA supplies Lercanidipino Tevagen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipino Tevagen is a calcium‑channel‑blocking antihypertensive that lowers elevated blood pressure.

Hypertension: lowers systolic and diastolic pressure in patients with primary hypertension. Isolated systolic hypertension: helps control elevated systolic pressure when diastolic values are normal. Essential hypertension: reduces cardiovascular risk by maintaining target blood pressure levels.

Lercanidipino Tevagen may cause a range of adverse reactions. Patients should be aware of both frequent and rare events.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth and redness, usually resolves spontaneously. - Peripheral edema: swelling of ankles or feet, may require monitoring. - Dizziness: especially upon standing, related to blood pressure lowering. - Fatigue: general tiredness without specific cause. - Tachycardia: increased heart rate in some individuals.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Arrhythmia: abnormal heart rhythms, potentially life‑threatening. - Angioedema: swelling of face, lips, tongue, or throat. - Hepatic enzyme elevation: abnormal liver function tests.

Before initiating therapy, clinicians should consider several safety factors.

Monitor blood pressure: ensure target levels are achieved without excessive drop. Assess renal function: adjust use in patients with severe renal impairment. Avoid abrupt discontinuation: sudden stop may cause rebound hypertension. Use with caution in elderly: increased sensitivity to hypotensive effects. Store at ambient temperature: keep below 25°C, protect from moisture and light.

Lercanidipino Tevagen can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic effect. - Grapefruit juice: can raise drug levels and risk of hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: additive blood‑pressure‑lowering effect, may require dose adjustment. - Beta‑blockers: combined use can enhance hypotensive response.